

1. Newman MF, Kirchner JL, Phillips-Bute B, et al; Neurological Outcome Research Group and the Cardiothoracic Anesthesiology Research Endeavors Investigators. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. *N Engl J Med*. 2001;344(6):395-402. doi:10.1056/NEJM200102083440601
2. Kapila AK, Watts HR, Wang T, Ma D. The impact of surgery and anesthesia on post-operative cognitive decline and Alzheimer's disease development: biomarkers and preventive strategies. *J Alzheimers Dis*. 2014;41(1):1-13. doi:10.3233/JAD-132258
3. Evered L, Silbert B, Scott DA, Zetterberg H, Blennow K. Association of changes in plasma neurofilament light and tau levels with anesthesia and surgery: results from the CAPACITY and ARCADIAN studies. *JAMA Neurol*. 2018;75(5):542-547. doi:10.1001/jamaneurol.2017.4913
4. Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. *Nat Med*. 2020;26(3):379-386. doi:10.1038/s41591-020-0755-1
5. Hesse C, Rosengren L, Andreassen N, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. *Neurosci Lett*. 2001;297(3):187-190. doi:10.1016/S0304-3940(00)01697-9
6. Neselius S, Brisby H, Theodorsson A, Blennow K, Zetterberg H, Marcusson J. CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. *PLoS One*. 2012;7(4):e33606. doi:10.1371/journal.pone.0033606

Rate of Recurrent Guillain-Barré Syndrome After mRNA COVID-19 Vaccine BNT162b2

On December 20, 2020, Israel initiated a national vaccination program against COVID-19. National and international vaccine guidelines did not preclude patients who have previously been diagnosed with Guillain-Barré Syndrome (GBS) from receiving the COVID-19 vaccine.^{1,2} However, previous association between vaccines and GBS raises the level of caution and hesitancy among clinicians and patients regarding administering the vaccine.³⁻⁵ The aim of this study was to establish rates of GBS relapse among Pfizer-BioNTech BNT162b2 vaccine receivers.

Methods | We performed a descriptive retrospective cohort study in the second largest health maintenance organization in Israel, Maccabi Healthcare Services (MHS), serving more than 2.5 million members, representing a quarter of the Israeli population. MHS has a nationwide centralized database, spanning more than 20 years, that includes extensive clinic and hospital diagnoses as well as vaccine registries. Data from the medical records were retrieved for all members who were recorded

as having an *International Classification of Diseases, Ninth Revision (ICD-9)* diagnosis code for GBS (code 357.0). To ensure that the correct patients with GBS diagnosis were identified, manual review of the electronic medical record was conducted of all cases. The criterion for a GBS case was a diagnosis given by a hospital neurology department. Data collected included information regarding GBS, vaccine administration, medical care encounters, and hospital visits after receiving at least 1 vaccine dose. The study was approved by the MHS institutional review board (0029-21-MHS).

Results | Seven hundred two cases of GBS were identified between 2000 and 2020. Three hundred thirty-seven (48%) were women and the mean (SD) age was 53 (18) years. Of these patients, 579 had received 1 vaccine dose and 539 received 2 doses. A median (IQR) of 108 (82 to 122) days' follow-up was obtained after the first vaccine administration and 90 (64 to 100) after the second. Of 40 patients who received only 1 dose of vaccine, 38 had COVID-19 previously and needed only 1 dose according to Israeli Ministry of Health guidelines.¹

Forty-eight of 579 patients were seen in a hospital (Table). Twenty-four had visited the emergency department and were released after less than 24 hours for transient non-neurologic concerns and the others needed admission for a variety of conditions. Only 5 were referred to the hospital for neurological concerns. Two patients had paresthesia, 1 patient had several months' duration of tremor, and 1 patient was evaluated for a seizure. They were released from the emergency department within a few hours without further medical observation. The fifth patient had a history of previously diagnosed GBS and was treated with plasmapheresis with no residual neurological symptoms. The patient had progressive leg weakness and paresthesia that started shortly after receiving the first vaccine dose, which lasted for several weeks. Several days following administration of the second vaccine dose, the patient was admitted to the hospital. The clinical picture and electrodiagnostic evidence were suggestive of sensorimotor demyelinating polyneuropathy. The patient was treated with plasmapheresis in the hospital and, by the day of discharge, had a significant improvement in her lower limb weakness and only minor proximal weakness without any sensory disturbance.

Table. Patients Who Have Been Previously Diagnosed With GBS and Hospital Visits Following COVID-19 Vaccine Administration^a

Case No./Sex/Age, y	Time from diagnosis to 1st/2nd vaccination, y	Hospital visits after 1st/2nd vaccination	Time from vaccination to hospital visit, d	Emergency department (1)/hospital admission (2)	Reason for hospital visit
1/M/80s	6	1st	0	1	Paresthesia
2/F/50s	14	1st	1	1	Paresthesia
3/F/50s	21	1st	2	1	Seizure
4/M/70s	17	1st	4	2	SOL lung
5/M/60s	3	1st	7	2	Diverticulitis
6/M/50s	15	1st	8	2	STEMI
7/M/60s	8	1st	8	2	Severe COVID-19
8/F/80s	21	1st	11	2	Severe COVID-19
9/F/60s	13	1st	15	1	Trauma

(continued)

Table. Patients Who Have Been Previously Diagnosed With GBS and Hospital Visits Following COVID-19 Vaccine Administration^a (continued)

Case No./Sex/Age, y	Time from diagnosis to first vaccination, y	Hospital visits after 1st/2nd vaccination	Time from vaccination to hospital visit, d	Emergency department (1)/hospital admission (2)	Reason for hospital visit
10/M/30s	4	1st	16	1	Tremor
11/F/30s	11	1st	16	2	Delivery
12/F/30s	8	1st	19	2	Surgery
13/M/60s	14	2nd	0	2	Surgery
14/M/70s	17	1st	23	1	Trauma
15/F/30s	2	2nd	3	2	GBS
16/F/50s	2	2nd	3	1	Vitreous detachment
17/M/70s	12	2nd	4	1	Epigastric distress
18/F/50s	6	2nd	5	1	Hypertension
19/F/40s	21	2nd	13	2	Fatigue
20/M/mid-teens	12	2nd	13	1	Lymphadenitis
21/M/60s	8	2nd	14	2	Surgery
22/F/50s	4	2nd	15	1	Trauma
23/F/60s	2	2nd	18	2	Surgery
24/M/40s	7	2nd	28	1	Chest pain
25/M/70s	16	2nd	28	2	Surgery
26/M/70s	17	2nd	29	1	Urinary retention
27/M/60s	7	2nd	30	2	Surgery
28/F/70s	1	2nd	31	1	Hypertension
29/M/60s	2	2nd	32	2	COPD exacerbation
30/M/70s	20	2nd	33	1	Suicide attempt
31/M/30s	5	2nd	33	1	Trauma
32/M/80s	8	2nd	34	2	Surgery
33/F/50s	14	2nd	37	1	Hemolytic anemia
34/M/60s	11	1st	60	1	Vomiting
35/M/60s	3	2nd	41	2	Upper GI tract bleeding
36/F/80s	15	2nd	49	1	Syncope
37/M/20s	7	2nd	53	1	Trauma
38/M/80s	8	2nd	56	2	Pneumonia
39/M/60s	12	2nd	57	2	Surgery
40/M/80s	1	2nd	57	1	Atrial fibrillation
41/M/70s	19	2nd	71	2	Pericarditis
42/F/60s	5	2nd	75	2	Trauma
43/M/70s	1	2nd	77	2	Surgery
44/F/70s	6	2nd	78	1	Cellulitis
45/F/60s	7	2nd	81	1	Trauma
46/M/50s	10	2nd	86	2	Surgery
47/M/70s	3	2nd	94	2	Trauma
48/M/60s	2	2nd	101	1	Trauma

Abbreviations: COPD, chronic obstructive lung disease; GI, gastrointestinal; GBS, Guillain-Barré syndrome; SOL, space-occupying lesion; STEMI, ST elevation myocardial infarction.

^a BNT162b2 (Pfizer-BioNTech) vaccine.

Discussion | To our knowledge, this is the first study assessing safety of messenger RNA COVID-19 vaccine in previously diagnosed cases of GBS. In this cohort study, which included 702 patients, only 1 needed short medical care for relapse of previous syndrome, which represents a minimal risk.

The study has limitations. First, it relies on medical records and diagnosis. However, a meticulous medical record inspection was conducted to validate all cases. Second, this study

included only hospital visits, which may underestimate other symptoms that presented only in the community. Nevertheless, any significant serious neurologic concern would probably have been evaluated in a hospital setting.

The Israeli Ministry of Health and national immunization guidelines did not include a history of GBS as a precaution or contraindication to receiving the COVID-19 vaccine, and our study supports this approach.

Shirley Shapiro Ben David, MD
Israel Potasman, MD
Daniella Rahamim-Cohen, MD

Author Affiliations: Health Division, Maccabi Healthcare Services, Tel Aviv, Israel (Shapiro Ben David, Rahamim-Cohen); Internal Medicine and Infectious Diseases, Maccabi Healthcare Services, Haifa, Israel (Potasman).

Accepted for Publication: August 5, 2021.

Published Online: September 1, 2021. doi:10.1001/jamaneurol.2021.3287

Corresponding Author: Shirley Shapiro Ben David, MD, Maccabi Healthcare Services, Hamered 27, Tel Aviv 6812509, Israel (shirley.shap@gmail.com).

Author Contributions: Dr Shapiro Ben David had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Shapiro Ben David.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: All authors.

Critical revision of the manuscript for important intellectual content: Rahamim-Cohen.

Supervision: Rahamim-Cohen.

Conflict of Interest Disclosures: None reported.

1. Israeli Ministry of Health. Coronavirus (COVID-19) vaccines. Accessed April 30, 2021. https://www.health.gov.il/UnitsOffice/HD/PH/epidemiology/td/docs/365_Corona.pdf.

2. Centers for Disease Control and Prevention. COVID-19 vaccines for people with underlying medical conditions. Accessed April 27, 2021. <https://www.cdc.gov/coronavirus/2019-ancov/vaccines/recommendations/underlying-conditions.html>.

3. Vellozzi C, Iqbal S, Broder K. Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. *Clin Infect Dis*. 2014;58(8):1149-1155. doi:10.1093/cid/ciu005

4. Martín Arias LH, Sanz R, Sáinz M, Treceño C, Carvajal A. Guillain-Barré syndrome and influenza vaccines: a meta-analysis. *Vaccine*. 2015;33(31):3773-3778. doi:10.1016/j.vaccine.2015.05.013

5. Lunn MP, Cornblath DR, Jacobs BC, et al. COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations. *Brain*. 2021;144(2):357-360. doi:10.1093/brain/awaa444

COMMENT & RESPONSE

Traumatic Brain Injury Recovery Trajectories in Patients With Disorders of Consciousness

To the Editor We congratulate Kowalski et al¹ for their longitudinal nested cohort of patients with moderate to severe traumatic brain injury (TBI) using the long-standing, federally supported Traumatic Brain Injury Model Systems (TBIMS) National Database,² which has 3 decades of follow-up. Their findings are remarkable in that the majority (82%) of initially comatose patients recovered consciousness after a stay in an inpatient rehabilitation center. More impressive is that 2 of 5 patients with disorders of consciousness (DOC) regained either partial or full independence. However, there are several interesting limitations that we thought were worth highlighting to the *JAMA Neurology* readership.

As the authors note, this represents a cohort of patients who were discharged from an acute care hospital to an inpatient rehabilitation center. Often a condition of acceptance to an inpatient rehabilitation hospital in the United States is insurance status. The parent TBIMS National Database cohort eligibility and selection procedures create a TBI sample that is more privileged, and with higher socioeconomic standing, than the larger TBI population with and without health insurance.³

This sample and selection bias would limit these results' real-world applicability, as approximately 20% to 40% of trauma patients are classified as uninsured or self-pay, depending on the institution.^{4,5}

Notably, at the time of admission to inpatient rehabilitation under the TBIMS umbrella, only 12% had a persistent DOC, improved from 57% on presentation. While only 2% were discharged from inpatient rehabilitation with DOC, it is clear the overall trajectory of this cohort during hospitalization and prior to rehabilitation was already toward an encouraging recovery. That said, we still find these results quite impressive and agree with the message that there should be caution in withdrawing or withholding support after severe TBI based on DOC. Shared and informed decision-making with surrogates and family members is ideal, given the potential for recovery, often only seen posthospitalization. We also fear false hope may be instilled in families at time of injury that more than 80% of comatose patients will recover.

We feel this study provides strong insight into the importance of recovery time and post-acute care rehabilitation in the continuum of management of a specific cohort of patients with TBI that are eligible for postdischarge inpatient rehabilitation. We hope for further work to expand the population receiving rehabilitation to patients of all socioeconomic backgrounds, irrespective of insurance status, to determine more widespread and equitable applicability of these encouraging findings.

Michael C. Smith, MD

Mayur B. Patel, MD, MPH

Oscar D. Guillamondegui, MD, MPH

Author Affiliations: Section of Surgical Sciences, Surgical Critical Care, and Emergency General Surgery, Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.

Corresponding Author: Michael C. Smith, MD, Department of Surgery, Vanderbilt University Medical Center, 1211 21st Ave S, 404 Medical Arts Bldg, Nashville, TN 37232 (michael.c.smith@vumc.org).

Published Online: October 4, 2021. doi:10.1001/jamaneurol.2021.3433

Conflict of Interest Disclosures: Dr Patel has received National Institutes of Health grants RO1GM120484, RO1AG058639, and IO1RX002992, a Haemonetics Investigator-Initiated Grant for Device Support, support from Liberate Medical SAB, and EAST Board of Directors Meeting travel support outside the submitted work and has a patent for Latent Image-Derived Features for Prognostic Modeling (publication WO2016134125 A1). No other disclosures were reported.

1. Kowalski RG, Hammond FM, Weintraub AH, et al. Recovery of consciousness and functional outcome in moderate and severe traumatic brain injury. *JAMA Neurol*. 2021;78(5):548-557. doi:10.1001/jamaneurol.2021.0084

2. Traumatic Brain Injury Model Systems National Data and Statistical Center. Welcome to the NDSC. Accessed March 4, 2021. <https://www.tbindsc.org/>.

3. Traumatic Brain Injury Model Systems National Data and Statistical Center. Standardized operating procedure IO1a: identification of subjects for the TBI Model Systems National Database. Accessed March 4, 2021. <https://www.tbindsc.org/StaticFiles/SOP/IO1a%20-%20Identification%20of%20Subjects.pdf>

4. Humble SS, Wilson LD, Wang L, et al. Prognosis of diffuse axonal injury with traumatic brain injury. *J Trauma Acute Care Surg*. 2018;85(1):155-159. doi:10.1097/TA.0000000000001852

5. Scott JW, Neiman PU, Uribe-Leitz T, et al. Impact of Affordable Care Act-related insurance expansion policies on mortality and access to post-discharge care for trauma patients: an analysis of the National Trauma Data Bank. *J Trauma Acute Care Surg*. 2019;86(2):196-205. doi:10.1097/TA.000000000000217